End-Payors Ink $30M Novartis Exforge Deal
Novartis has reached another deal to shake off claims that it hatched an illegal deal with Par Pharmaceuticals to delay the release of a generic version of the blood pressure drug...To view the full article, register now.
Already a subscriber? Click here to view full article